Document Detail

Outcome measures of chinese herbal medicine for coronary heart disease: an overview of systematic reviews.
Jump to Full Text
MedLine Citation:
PMID:  22606207     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Objective. The aim of this overview was to summarize the outcome measures of Chinese herbal medicine (CHM) as the treatment of coronary heart disease (CHD) based on available systematic reviews (SRs), so as to display the current situation and evaluate the potential benefits and advantages of CHM on CHD. Methods. An extensive search included the Cochrane Database of Systematic Reviews, MEDLINE, and 4 databases in Chinese. SRs of CHM for CHD were included. Besides evaluating and summarizing the outcome measures, we also estimated the quality of the included reviews by PRISMA (preferred reporting items for systematic reviews and meta-analyses). Data were extracted according to predefined inclusion criteria by two independent reviewers. Results. 46 articles were included. 20 kinds of CHM were reviewed. 7 SRs were concerned with myocardial infarction (MI), 38 SRs were related to angina pectoris. 11 SRs had primary endpoints, while others focused on secondary endpoints to evaluate CHM for CHD such as angina pectoris and electrocardiogram (ECG). One SR reported more adverse effects of CHM for CHD and of the SRs analyzed quality of life. Many CHM appeared to have significant effect on improving symptoms, ECG, biomarkers and so on. However, most SRs failed to make a definite conclusion for the effectiveness of CHM in CHD patients due specifically to the poor evidence. And according to PRISMA we found most of the trials in the SRs were of low quality. Conclusion. Primary endpoints were not used widely. The benefits of CHM for CHD need to be confirmed in the future with RCTs of more persuasive primary endpoints and high-quality SRs.
Authors:
Jing Luo; Hao Xu
Related Documents :
12422157 - Assessment of residual myocardial viability in regions with chronic electrocardiographi...
2582657 - Prognostic significance of postinfarction arrhythmias and biventricular dysfunction und...
6697457 - Assessment of regional left ventricular relaxation in patients with coronary artery dis...
16139137 - Prognostic significance of left anterior hemiblock in patients with suspected coronary ...
18793547 - Significance of tei-index alterations induced by acute preload reduction with hemodialy...
11005597 - Complete transposition of the great arteries: surgical concepts for patients with syste...
Publication Detail:
Type:  Journal Article     Date:  2012-04-23
Journal Detail:
Title:  Evidence-based complementary and alternative medicine : eCAM     Volume:  2012     ISSN:  1741-4288     ISO Abbreviation:  Evid Based Complement Alternat Med     Publication Date:  2012  
Date Detail:
Created Date:  2012-05-18     Completed Date:  2012-08-23     Revised Date:  2013-04-08    
Medline Journal Info:
Nlm Unique ID:  101215021     Medline TA:  Evid Based Complement Alternat Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  927392     Citation Subset:  -    
Affiliation:
Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Evid Based Complement Alternat Med
Journal ID (iso-abbrev): Evid Based Complement Alternat Med
Journal ID (publisher-id): ECAM
ISSN: 1741-427X
ISSN: 1741-4288
Publisher: Hindawi Publishing Corporation
Article Information
Download PDF
Copyright © 2012 J. Luo and H. Xu.
open-access:
Received Day: 24 Month: 11 Year: 2011
Accepted Day: 26 Month: 1 Year: 2012
Print publication date: Year: 2012
Electronic publication date: Day: 23 Month: 4 Year: 2012
pmc-release publication date: Day: 23 Month: 4 Year: 2012
Volume: 2012E-location ID: 927392
ID: 3347864
PubMed Id: 22606207
DOI: 10.1155/2012/927392

Outcome Measures of Chinese Herbal Medicine for Coronary Heart Disease: An Overview of Systematic Reviews
Jing Luo1, 2I2
Hao Xu2*
1Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China
2Cardiovascular Diseases Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
Correspondence: *Hao Xu: xuhaotcm@gmail.com
[other] Academic Editor: Keji Chen

1. Introduction

Coronary heart disease (CHD) is the most common cause of death in western countries. With the infectious diseases controlled and improvement of people's living, the morbidity of CHD increases year by year in many developing countries. Acute myocardial infarction (AMI) and angina pectoris are the most important two types of CHD. Chinese herbal medicine (CHM) has a 3000-year-old history with unique theories for concepts of etiology and systems of diagnosis and treatment [1]. The interest in CHM is growing rapidly beyond China [25]. In recent years, some researchers have reported the effect of CHM on clinical symptoms, biomarkers and mortality in CHD patients. However, the evidence of CHM needs to be reviewed systematically and appraised critically.

High-quality systematic reviews (SRs) of randomized controlled trials (RCTs) are the sources of the best evidence [6]. Currently, there is an increasing number of SRs on studies of CHM, but few of them concluded that CHM was definitely effective for CHD due to the weak evidence. In addition to rigorous clinical design and standard reporting, the selection of outcome measures also plays an important role in drawing a more persuasive conclusion. The aim of this overview was to summarize the outcome measures of CHM as the treatment of CHD based on available SRs, so as to display the current situation and evaluate the potential benefits and advantages of CHM on CHD.


2. Methods

Electronic literature searches were performed to identify the maximum possible number of systematic reviews/meta-analyses of CHM for CHD. The following electronic databases were searched: (1) The Cochrane Database of Systematic Reviews (Issue 10 of 12, Oct 2011); (2) MEDLINE (2001 to 2011); (3) Chinese Biomedical Database (CBM, 2001 to 2011); (4) China National Knowledge Infrastructure (CNKI, 2001 to 2011); (5) Wanfang Databases (2001 to 2011); (6) Chinese VIP Information (VIP, 2001 to 2011). CBM, CNKI, Wanfang, and VIP were databases in Chinese. We searched databases in Chinese because CHMs were researched in china mostly. And we searched papers from 2001 to 2011 for high-quality RCTs and SRs mainly focusing in recent ten years.

The strategy below was used to search The Cochrane Library and adapted appropriately for use in different electronic bibliographic databases: #1 herb*; #2 medic*; #3 (#1 and #2); #4 Chinese; #5 (#3 or #4); #6 cardiac; #7 heart; #8 circulation; #9 (#6 or #7 or #8); #10 (#5 and #9). To determine which article was we want, we scanned the title and abstract of each record independently by two reviewers (J. Luo and H. Xu). If the information included a systematic review or a meta-analysis of CHM for CHD, the full paper was obtained for further assessment. Papers were excluded when problems occurred with: repeat publication; methodological studies; quality assessment report; the interventions in the control groups were other Chinese herbs; research on acupuncture, qigong, massage, or other treatments (Figure 1).

We divided the outcome measures into primary endpoints and secondary endpoints [50, 51]. Primary endpoints include the mortality, AMI, restenosis after percutaneous coronary intervention (PCI), and recanalization. Secondary endpoints mainly indicate surrogate endpoints and laboratory measures, which include angina pectoris, arrhythmia, heart failure, consumption of nitroglycerine, electrocardiogram (ECG), ultrasonic cardiogram (UCG), Level of blood lipids, plasma endothelin, nitric oxide, myocardial enzyme, hemorheology, heart rate variability, and traditional Chinese medicine (TCM) syndrome.

In addition, we used PRISMA (preferred reporting items for systematic reviews and meta-analyses) as assessment tool to estimate the quality of the included reviews. This checklist includes 27 items of 7 key areas. And it describes the preferred way to present the abstract, introduction, methods, results, and discussion sections of a systematic review and a meta-analysis paper. It requires authors of each review to include a flow diagram that provides information about the number of studies identified, included, and excluded and the reasons for excluding them [52]. Information on each of the included reviews was imported into PRISMA statement for analysis. All data were extracted independently by two authors using predefined criteria. Disagreements were resolved by discussion between the authors. All inconsistencies were revised after a consensus was reached.


3. Results

46 articles were included (7 in English and 39 in Chinese). 39 SRs from the Chinese databases were published between 2004 and 2011. Since 2007, the number of SR increased markedly. 5 SRs from the Cochrane Database were published between 2006 to 2011 [8, 13, 26, 36, 44]. 2 SRs from MEDLINE were published between 2006 to 2011 [14, 45].

7 SRs were concerned with myocardial infarction (MI), 38 SRs were related to angina pectoris, and one SR was concerned with preventing and treating restenosis after PCI. The trials in SRs were mainly originated from china. The original trials included were called “RCTs” or “quasi-RCTs”, but only a few of them were typical RCTs. Most of the trials in the SRs were of low quality, only 14 RCTs were high quality: one was concerned with MI, 12 were related to angina pectoris, and one was about preventing and treating restenosis.

20 kinds of CHM were reviewed, including injections, capsules, tablets, pellets, and herbal decoction as follows: Danshen preparations (n = 13) [8, 14, 2022, 33, 3841, 4547], 7 of them were compound salvia pellet [14, 22, 33, 38, 4547]; Tongxinluo Capsule (n = 4) [13, 22, 27, 37]; Yiqi huoxue (supplementing qi and activating blood circulation) products (n = 3) [10, 32, 49]; Xuefu zhuyu decoction (n = 2) [23, 30]; herbal products (n = 4) [11, 12, 17, 26]; Shengmai injection (n = 2) [9, 24]; Suxiao jiuxin wan (n = 2) [35, 36]; Gingko (n = 2) [28, 29]; Acanthopanax (n = 2) [53, 54]; Puerarin (n = 2) [15, 44]; Shexiang baoxin wan (n = 2) [34, 55]; Shenmai injection (n = 1) [7]; Tetramethylpyrazine (n = 1) [43]; Shuxuetong (n = 1) [48]; Xinkeshu (n = 1) [31]; Safflower injection (n = 1) [25]; Rhodiola (n = 1) [42]; Kudiezi injection (n = 1) [19]; Shuyu zaogan tablets (n = 1) [18]; Dengzhanhua injection (n = 1) [16].

11 SRs analyzed primary endpoints and the others all focused on secondary endpoints to evaluate CHM for CHD (Table 1). This was mainly based on whether there were available data in the original trials or not. Four primary endpoints were analyzed in the SRs including mortality, nonfatal myocardial infarction, restenosis after PCI, and recanalization. None of these SRs analyzed the quality of life. Angina pectoris was the most common secondary endpoint in the SRs. There was one SR without clear outcome measures [53], and 2 SRs only used “marked effective,” “effective,” “ineffective” as comprehensive outcome measures involving symptoms improvement and ECG changes [19, 54]. Many CHMs appear to have significant effect on improving symptoms, ECG, and level of blood lipids and reducing the consumption of nitroglycerine, and so forth. Some SRs also reflected that CHM may be effective to reduce the risk of subsequent MI, heart failure, and arrhythmia. However, most SRs failed to draw a definite conclusion of the effectiveness of CHM for CHD due specifically to the poor evidence.

Adverse effects, which are important when evaluate a medicine, should be regarded as an essential outcome measure in clinical trials. However, only a few of the trials in the SRs had long-term data on adverse effects. Most of adverse effects of CHM were mentioned as “low adverse effect” or “none obvious”. The adverse events reported majorly were abdominal complaints, nausea, and dyspepsia. One review reported more adverse reactions in treatment groups than in control groups [44]. Recently, several reviews have highlighted adverse reactions of CHM [56, 57].

Compared the usage of outcome measures between Cochrane and non-Cochrane reviews, we found that outcome measures of the included papers in Cochrane are more comprehensive. Every Cochrane review took primary endpoints, secondary endpoints, and safety as outcome measures. However, primary endpoints and safety are seldom taken as outcome measures in most of the non-Cochrane reviews. None of reviews analyzed quality of life or pay attention to medical economics.

According to PRISMA statement, we found that most of the included reviews are of low quality. The deficiencies are as follows: review methods in the abstracts and rationales for review were not well reported; only about half of the SRs reported the characteristics of included trials; just 5 SRs provided flow chart in the article, 2 in Chinese [22, 29], and 3 in English [8, 14, 26]; potential biases were not described well in the reports; most SRs lack in persuasive outcome measures.


4. Discussion

Our overview shows that primary endpoints and secondary endpoints are all used to evaluate the effect of CHM for CHD. Secondary endpoints are most commonly adopted in clinical trials due to their feasibility in small sample size and short-term clinical trials. They may signify future cardiovascular event to some extent and are sure to be valuable as surrogate endpoints. But it is clearly that primary endpoints are more persuasive in RCT of cardiovascular diseases. However, most of the outcome measures in the included SRs are angina pectoris and ECG. Primary endpoints such as mortality and major cardiovascular events are not used widely. Adverse effects, quality of life, and medical economics, which are also important when evaluate a medicine, should be taken as outcome measures too. All of these are the reasons why neither the trials nor the SRs of CHM for CHD could meet a sufficiently high standard to be broadly accepted by the Western medical community.

SRs of CHM with poor methodology and reporting quality have been reported [58]. According to PRISMA statement, we found that most of the included reviews have poor quality. Reviewers were not good at reporting how they avoided bias in selecting primary studies, how they extracted data, and how they evaluated the validity of the primary studies. Also, most of the reviewers chose less persuasive outcome measures, which reduced the persuasion of the interventions. So if reviewers did not master the method of performing SR, they could produce inaccurate or misleading conclusions for current clinical practice and even the future research. Although it appeared that CHM was effective for CHD in clinical use, such as compound salvia pellet, shengmai injection, suxiao jiuxin wan, and gingko, puerarin, most SRs were inconclusive that CHM had a definite effect for CHD owing to the poor evidence.

Before recommending the conclusion, we have to consider the following weaknesses in this overview. Firstly, data were abstracted from SRs instead of the original trials, and most of the included SRs have poor quality. Secondly, most of the RCTs in the SRs included are also of low quality due mainly to unclear randomization and blinding method, incomplete outcome reporting, publication bias, and so forth. Thirdly, we only selected SRs published in Chinese and English. SRs of CHM for CHD published in other language or originated from other countries might be omitted. Fourthly, we did not identify unpublished studies, thus negative trial might not be reported and could induce publication bias.

In conclusion, primary and secondary endpoints were all used to evaluate the effectiveness of CHM for CHD, but primary endpoints were not used widely. Although it appeared that CHM was effective for CHD in terms of some outcome measures, most SRs failed to draw a definite conclusion for the effectiveness of CHM in CHD patients due to the poor evidence. The benefits of CHM for CHD still need to be confirmed in the future with RCTs of more persuasive primary endpoints and high-quality SRs.


References
1. Chen KJ,Xu H. The integration of traditional Chinese medicine and Western medicineEuropean ReviewYear: 2003112225235
2. Robinson N. Integrative medicine—traditional Chinese medicine, a model?Chinese Journal of Integrative MedicineYear: 2011171212521258892
3. Dobos G,Tao I. The model of western Integrative medicine: the role of Chinese medicineChinese Journal of Integrative MedicineYear: 2011171112021258891
4. Tindle HA,Davis RB,Phillips RS,Eisenberg DM. Trends in use of complementary and alternative medicine by US adults: 1997–2002Alternative Therapies, Health and MedicineYear: 20051114249
5. Eisenberg D. Reflections on the past and future of integrative medicine from a lifelong student of the integration of Chinese and western medicineChinese Journal of Integrative MedicineYear: 20111713521258889
6. Medical Research Library of BrooklynThe Evidence Pyramid http://library.downstate.edu/EBM2/2100.htm.
7. Zeng YJ,Wang J,Zhou YC,Huang MX. Effect of shenmai injection on mortality rate of patients with acute myocardial infartion: a systematic reviewModern Journal of Integrated Traditional Chinese and Western MedicineYear: 2010192835553558
8. Wu T,Ni J,Wu J. Danshen (Chinese medicinal herb) preparations for acute myocardial infarctionCochrane Database of Systematic ReviewsYear: 20082, article CD004465
9. Gao ZY,Guo CY,Shi DZ,Chen KJ,Xu H,Guo TX. Effect of Shengmai injection on the fatality rate of patients with acute myocardial infarction: a Systematic reviewChinese Journal of Integrated Traditional and Western MedicineYear: 200828121069107319317159
10. Zhang JH,Shang HC,Zhang BL,Gao XM,Xiang YZ,Wang H. Systematic review of randomized controlIed trials on treatment of myocardial infarction with YiqiHuoxue Chinese Patent medicineChina Journal of Traditional Chinese Medicine and PharmacyYear: 2008234300306
11. Zhen L,Liu HX,Shang JJ. Effect of herbal injection products as adjutant treatment on mortality rate and recanalization rate of patients with acute myocardial infartion: a Meta AnalysisJournal of Emergency in Traditional Chinese MedicineYear: 2007167859862
12. Lin Q,Nong YB,Duan WH. Meta analysis of clinical research literature on Chinese materia medica for acute myocardial infarctionChina Journal of Traditional Chinese Medicine and PharmacyYear: 200621952955631
13. Wu T,Harrison RA,Chen X,et al. Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectorisCochrane database of systematic reviews (Online)Year: 20064, article CD004474
14. Zhang JH,Shang HC,Gao XM,et al. Compound salvia droplet pill, a traditional Chinese medicine, for the treatment of unstable angina pectoris: a systematic reviewMedical Science MonitorYear: 2008141RA1RA718160949
15. Wang J,Tian Y,Feng C,Sheng H. Effect of Puerarin injection for unstable angina pectoris: a Systematic ReviewGuangming Journal of Chinese MedicineYear: 2008234399403
16. Cao W,Lan D,Zhang T,Tang C,Wu TX,Liu GJ. Effect of Dengzhanhua Injection for angina pectoris: a systematic reviewChinese Journal of Evidence-Based MedicineYear: 200554317322
17. Ren Y,Chen KJ,Ruan XM. Systematic review of randomized controlled trials on preventing and treating restenosis after percutaneous coronary intervention with Chinese medicineChinese Journal of Integrated Traditional and Western MedicineYear: 200828759760118822907
18. Zhang ZH,Chen ZJ,Sheng YC,et al. Systematic evaluation of Shuyu Zaogan tablets for coronary heart diseaseWorld Clinical DrugsYear: 2011323159164
19. Zuo ZJ,Huang QM. A systematic review of Kudiezi injection in the treatment of angina pectorisChina Medical HeraldYear: 2011843235
20. Wang Cl,Gu F,Wang SL. Meta-analysis on randomized controlled trials for treatment of angina pectoris by sodium tanshinone IIA sulfonateChinese Journal of Integrative Medicine on Cardio/Cerebrovascular DiseaseYear: 201196644647
21. Xu GL,Lin SM,Xu H,Qin L. Meta-analysis of Danhong injection for unstable angina pectorisLi Shizhen Medicine and Materia Medica ResearchYear: 2011223765767
22. Jia YL,Zhang SK,Bao FF,Huang FY,Liang SW. Indirect Comparison of Tongxinluo capsule and Danshen dripping pill for angina pectoris: a Systematic ReviewChinese Journal of Evidence-Based MedicineYear: 2011118919931
23. Cui HJ,He HY,Xing ZH. System Evaluation and Meta Analysis of Xuefuzhuyu Decoction on unstable angina pectorisJournal of Emergency in Traditional Chinese MedicineYear: 201120710711074
24. Zhang Q,Jin RM. Meta-analysis of Shengmai injection and conventional therapy for coronary heart diseaseChinese Journal of New Drugs and Clinical RemediesYear: 2010294310314
25. Wu FB,Xu T,Li J,Tang Y. Meta Analysis on Efficacy and Safety of Safflower Injection in Treating unstable angina pectorisChina PharmaceuticalsYear: 2010191745
26. Zhuo Q,Yuan Z,Chen H,Wu T. Traditional Chinese herbal products for stable anginaCochrane database of systematic reviews (Online)Year: 20105, article CD004468
27. Hao CH,Zhang JY. Meta-analysis of Tongxinluo Capsule for coronary heart disease anginaChina Modern DocterYear: 2010481469
28. Zha Y,Li L. Systematic Evaluation of Yinxing Damo injection in the treatment of angina pectorisChina PharmacyYear: 2010 214441434147
29. Zhao W,Xiang JS,Ye K. Systematic Review on Randomized Controlled Trials for treatment of UAP by Ginkgo extractJournal of Liaoning University of Traditional Chinese MedicineYear: 20101211216220
30. Song XM. Effect of Xuefuzhuyu decoction as adjutant treatment to isosorbide dinitrate and aspirin for coronary angina pectoris: a Meta-analysisThe Journal of Practical MedicineYear: 2010261426332635
31. Chen XT,Guo SE,Guo Y. Effect of Xinkeshu for coronary angina pectoris: a Meta-analysisJournal of Changchun University of Traditional Chinese MedicineYear: 2010263357359
32. Long Y,Jin X,Shao ZJ,Ma J,Li JH,Xiao TH. Systematic review on randomized controlled trials for qi-supplementing and blood-quickening treatment of angina pectoris due to qi-deficiency and blood stasisChina Heart JournalYear: 20092115459
33. Zhang MZ,Zhang J. Meta-analysis of Compound salvia pellet for coronary heart diseaseLi Shizhen Medicine and Materia Medica ResearchYear: 200920410071008
34. Lin H,Tang WP. Systematic Review of Randomized Controlled Trials on treating CHD with Shexiang baoxin wanFirst National Middle-Aged MD Forum Proceedings of Integrative Medicine on Cardiovascular DiseaseYear: 2008147152
35. Wang XJ,Xu BN. Meta Analysis on treating angina pectoris with Suxiao jiuxin pillShaanxi Journal of Traditional Chinese MedicineYear: 200829912491251
36. Duan X,Zhou L,Wu T,et al. Chinese herbal medicine suxiao jiuxin wan for angina pectorisCochrane Database of Systematic ReviewsYear: 20081, article CD004473
37. He SZ,Wu WK,Deng ZS,Ou SY,Liu SF. Systematic Review on Randomized Controlled Trials for treatment of coronary heart disease by Tong xin luo CapsulJournal of Sun Yat-Sen UniversityYear: 2007285573577
38. Jiang SY,Tong JC,Shun RY,Xie HT. Meta-analysis of Compound salvia pellet for coronary angina pectorisPractical Pharmacy and Clinical RemediesYear: 2007106334337
39. Li KJ. A systematic review on Randomized Controlled Trials for treatment of unstable angina pectoris with Danshen preparationsGuangming Journal of Chinese MedicineYear: 20082223740
40. Zhang JH,Shang HC,Gao XM,et al. Systematic evaluation of Compound preparation of salvia miltiorrhiza in treating stable angina in a randomized controlled trialTianjin Journal of Traditional Chinese Medicine Year: 2007243195200
41. Li KJ. A systematic review on randomized controlled trials for treatment of stable angina pectoris with Danshen preparationsHerald of MedicineYear: 2007264383386
42. Wang X,Zhu YY,Hu LS. A Systematic review of Rhodiola L. for treating anginaProgress in Modern BiomedicineYear: 2006624245
43. Zhang YC,Zhi FC,Tan QX,He J. Treating unstable angina with tetramethylpyrazine: a systematic reviewChinese Journal of Clinical RehabilitationYear: 20061027102104
44. Wang Q,Wu T,Chen X,et al. Puerarin injection for unstable angina pectorisCochrane Database of Systematic ReviewsYear: 20063, article CD004196
45. Wang G,Wang L,Xiong ZY,Mao B,Li TQ. Compound salvia pellet, a traditional Chinese medicine, for the treatment of chronic stable angina pectoris compared with nitrates: a meta-analysisMedical Science MonitorYear: 2006121SR1SR716369479
46. Wang L,Xiong ZY,Wang G. Systematic assessment on randomized controlled trials for treatment of stable angina pectoris by compound salvia pelletChinese Journal of Integrated Traditional and Western MedicineYear: 200424650050415250200
47. Zhang MZ,Wang L,Chen BJ,Nie GN. Meta-analysis of Document on Compound Danshen dropping pills (DSP) in Treatment of patients with Stable AnginaChinese Journal of Integrative Medicine Cardio/Cerebrovascular DiseaseYear: 200426311314
48. Li XY,Du F,Cheng WL,Xia H. Systematic review on randomized controlled trials for treatment of unstable angina pectoris by ShuxuetongModern Journal of Integrated Traditional Chinese and Western MedicineYear: 2010191822312233
49. Song QG,Du WX,Liu M,et al. Effect of Yiqi Huoxue herbal products for ventricular remodeling after acute myocardial infarction: a Meta-analysisLiaoning Journal of Traditional Chinese MedicineYear: 2008353323325
50. European Medicines Agency (EMA)Committee for medicinal products for human use, Guideline on the evaluation of medicinal products for cardiovascular Disease prevention London, 2008 http://www.ema.europa.eu/ema/index/.
51. Yusuf S,Mehta S,Anand S,et al. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme: rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular diseaseEuropean Heart JournalYear: 200021242033204111102254
52. Moher D,Liberati A,Tetzlaff J,Altman DG. The PRISMA Groupl. Preferred Reporting Items for Systematic Reviews and Meta-analyses:The PRISMA statementPLOS MedYear: 200967, article e1000097
53. Wang P,Xu YG,Gao ZY. Effect of Acanthopanax Senticosus injection for coronary angina pectoris: a Meta-analysisLishizhen Medicine and Materia Medica ResearchYear: 200718922432244
54. Zhong ZH,Li WH. A Meta Analysis on Randomized Controlled Trials for treatment of coronary angina pectoris with Acanthopanax Senticosus injectionChina PharmaceuticalsYear: 2007161556
55. Zhou XG,Wang HW,Yu GB. Meta Analysis on treating unstable angina pectoris with Shexiang baoxin wanChinese Traditional Patent MedicineYear: 200426supplement16
56. Guo LM,Feng YG. Adverse reaction of puerarin injectionChinese Magazine of Clinical Medicinal Professional ResearchYear: 2003691149511497
57. Zhi LM,Zhang ZQ. Review on the adverse reactions of puerarin injectionHebei Traditional Chinese MedicineYear: 2002247555556
58. Zhang JH,Shang HC,Gao XM,et al. Methodology and reporting quality of systematic review/meta-analysis of traditional Chinese medicineJournal of Alternative and Complementary MedicineYear: 2007138797805

Article Categories:
  • Review Article


Previous Document:  Curcumin-induced apoptosis in human hepatocellular carcinoma j5 cells: critical role of ca(+2)-depen...
Next Document:  The effect of abdominal radical trachelectomy on ovarian reserve: serial changes in serum anti-müll...